免疫原性
药品
结合
肽
癌症治疗
计算生物学
医学
纳米技术
药理学
癌症
化学
生物
抗体
免疫学
材料科学
内科学
生物化学
数学分析
数学
作者
Ruirong Tan,Zhenya Yang,Xie Jun,Zijun Wu,Shanshan Guo,Li Li,Zhujun Yin,Hua Hua,Miao Liu,Rui Li
标识
DOI:10.1097/cm9.0000000000003438
摘要
ABSTRACT: Peptide-drug conjugates (PDCs) have emerged as a promising strategy in cancer therapy, offering improved therapeutic efficacy and reduced toxicity. Compared to antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), PDCs possess distinct advantages, such as lower immunogenicity, improved tumor penetration, and simpler synthesis. This review discusses the latest advancements in PDC design, including novel peptide targeting mechanisms, linker selection, and formulation improvements for increased stability. Additionally, it explores the expanding clinical applications of PDCs and examines their limitations. The aim of this review is to provide a comprehensive overview of current PDC progress and outline future directions for their role in cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI